Editorial Policies

This website is intended to provide the Group's stakeholders, including patients, medical professionals, shareholders, investors, local communities, and employees, with information about the CSR activities implemented by the Group in fiscal 2018. Specific initiatives implemented in accordance with the Company's philosophy are presented in line with the ISO 26000 Core Subjects.
The CSR Activities Report 2019 PDF version, which contains the same content as disclosed on this website, can be downloaded from the CSR Activities Report archive page.
The principal environmental and social performance indicators included in the CSR Activities Report 2019 PDF version received third-party assurance from KPMG AZSA Sustainability Co., Ltd. from an independent perspective. Please click here to see the PDF version.
Explanations of medical and pharmaceutical terms appearing in this report have been provided to foster a wider understanding of the report's content.

Applied Guidelines
  • ISO26000;
  • Global Reporting Initiative (GRI) Sustainability Reporting Standard;
  • Environmental Reporting Guidelines, 2018 version, published by the Ministry of the Environment of Japan
Period covered April 1, 2018, to March 31, 2019
(The report includes examples of activities from April 2019 and thereafter.)
Issue timing September 2019 (Previous report: September 2018; next report: September 2020)
Scope of reporting Mitsubishi Tanabe Pharma and consolidated subsidiaries in Japan and overseas.
(The scope of reporting could differ in accordance with the examples being reported.)
Contact information

Contact Us